BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29801721)

  • 1. Can dose outside the PTV influence the risk of distant metastases in stage I lung cancer patients treated with stereotactic body radiotherapy (SBRT)?
    Diamant A; Chatterjee A; Faria S; Naqa IE; Bahig H; Filion E; Robinson C; Al-Halabi H; Seuntjens J
    Radiother Oncol; 2018 Sep; 128(3):513-519. PubMed ID: 29801721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetric parameters related to occurrence of distant metastases and regional nodal relapse after SBRT for early-stage non-small cell lung cancer.
    Lalonde R; Abdelhakiem M; Keller A; Huq MS
    Radiother Oncol; 2022 Apr; 169():90-95. PubMed ID: 35202740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer in the very elderly (≥80years old): Extremely safe and effective.
    Kreinbrink P; Blumenfeld P; Tolekidis G; Sen N; Sher D; Marwaha G
    J Geriatr Oncol; 2017 Sep; 8(5):351-355. PubMed ID: 28739159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing local control and distant metastasis in NSCLC patients between CyberKnife and conventional SBRT.
    Diamant A; Heng VJ; Chatterjee A; Faria S; Bahig H; Filion E; Doucet R; Khosrow-Khavar F; Naqa IE; Seuntjens J
    Radiother Oncol; 2020 Mar; 144():201-208. PubMed ID: 32044418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
    Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
    Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy.
    Shaverdian N; Tenn S; Veruttipong D; Wang J; Hegde J; Lee C; Cao M; Agazaryan N; Steinberg M; Kupelian P; Lee P
    Br J Radiol; 2016; 89(1059):20150963. PubMed ID: 26764282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
    Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
    J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic body radiotherapy for stage I non-small-cell lung cancer using higher doses for larger tumors: results of the second study.
    Miyakawa A; Shibamoto Y; Baba F; Manabe Y; Murai T; Sugie C; Yanagi T; Takaoka T
    Radiat Oncol; 2017 Sep; 12(1):152. PubMed ID: 28893300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton beam radiotherapy versus three-dimensional conformal stereotactic body radiotherapy in primary peripheral, early-stage non-small-cell lung carcinoma: a comparative dosimetric analysis.
    Macdonald OK; Kruse JJ; Miller JM; Garces YI; Brown PD; Miller RC; Foote RL
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):950-8. PubMed ID: 19801106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of Nodal and Metastatic Failure in Early Stage Non-small-cell Lung Cancer After Stereotactic Body Radiation Therapy.
    Cerra-Franco A; Liu S; Azar M; Shiue K; Freije S; Hinton J; Deig CR; Edwards D; Estabrook NC; Ellsworth SG; Huang K; Diab K; Langer MP; Zellars R; Kong FM; Wan J; Lautenschlaeger T
    Clin Lung Cancer; 2019 May; 20(3):186-193.e3. PubMed ID: 30711394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeat stereotactic body radiotherapy (SBRT) for local recurrence of non-small cell lung cancer and lung metastasis after first SBRT.
    Ogawa Y; Shibamoto Y; Hashizume C; Kondo T; Iwata H; Tomita N; Ogino H
    Radiat Oncol; 2018 Jul; 13(1):136. PubMed ID: 30055636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of Distant Failure After Stereotactic Body Radiation Therapy for Stages I to IIA Non-Small-Cell Lung Cancer.
    Miller CJ; Martin B; Stang K; Hutten R; Alite F; Small C; Emami B; Harkenrider MM
    Clin Lung Cancer; 2019 Jan; 20(1):37-42. PubMed ID: 30279109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-response relationship with clinical outcome for lung stereotactic body radiotherapy (SBRT) delivered via online image guidance.
    Kestin L; Grills I; Guckenberger M; Belderbos J; Hope AJ; Werner-Wasik M; Sonke JJ; Bissonnette JP; Xiao Y; Yan D;
    Radiother Oncol; 2014 Mar; 110(3):499-504. PubMed ID: 24630539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three- Versus Five-Fraction Regimens of Stereotactic Body Radiotherapy for Peripheral Early-Stage Non-Small-Cell Lung Cancer: A Two-Institution Propensity Score-Matched Analysis.
    Ma SJ; Cummings M; Serra LM; Syed YA; Hermann GM; Chen Y; Milano MT; Singh AK; Gomez-Suescun JA; Singh DP
    Clin Lung Cancer; 2018 May; 19(3):e297-e302. PubMed ID: 29254649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Planning benchmark study for SBRT of early stage NSCLC : Results of the DEGRO Working Group Stereotactic Radiotherapy.
    Moustakis C; Blanck O; Ebrahimi Tazehmahalleh F; Ka Heng Chan M; Ernst I; Krieger T; Duma MN; Oechsner M; Ganswindt U; Heinz C; Alheit H; Blank H; Nestle U; Wiehle R; Kornhuber C; Ostheimer C; Petersen C; Pollul G; Baus W; Altenstein G; Beckers E; Jurianz K; Sterzing F; Kretschmer M; Seegenschmiedt H; Maass T; Droege S; Wolf U; Schoeffler J; Haverkamp U; Eich HT; Guckenberger M
    Strahlenther Onkol; 2017 Oct; 193(10):780-790. PubMed ID: 28567503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response criteria in solid tumors (PERCIST/RECIST) and SUV
    Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
    Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer.
    Baine MJ; Verma V; Schonewolf CA; Lin C; Simone CB
    Lung Cancer; 2018 Apr; 118():20-26. PubMed ID: 29571997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiation therapy with higher biologically effective dose is associated with improved survival in stage II non-small cell lung cancer.
    Yan SX; Qureshi MM; Dyer M; Truong MT; Mak KS
    Lung Cancer; 2019 May; 131():147-153. PubMed ID: 31027693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeat stereotactic body radiation therapy (SBRT) for salvage of isolated local recurrence after definitive lung SBRT.
    Kennedy WR; Gabani P; Nikitas J; Robinson CG; Bradley JD; Roach MC
    Radiother Oncol; 2020 Jan; 142():230-235. PubMed ID: 31481272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.